Heralded as a longevity treatment for bio-hacking enthusiasts and tech CEOs, therapeutic plasma exchange also has applications for people concerned about inflammatory diseases like…
ApoE4, a genetic variation sometimes referred to as the “Alzheimer’s gene,” is one of the most influential genetic risk factors for developing Alzheimer’s disease….
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
Would you still participate in an Alzheimer’s clinical trial if you found out that because of your genetics, you were more vulnerable to serious…
In the 1950s, doctors Carlton Gajdusek and Vincent Zigas trekked over mountains and across rivers to study a mysterious and fatal neurological disease called…
Changes in thinking and memory as we age can occur for a variety of reasons. These changes are not always cause for concern. But…
This article is part of the Journey to Diagnosis series, produced by Being Patient with support provided by Eli Lilly. In the newest definition…
Hardly a week goes by when I don’t receive an email or a call from a friend whose parent has just gotten an Alzheimer’s…
Precision medicine is a medical approach that considers a patient’s genes, environment, and lifestyle. In the realm of Alzheimer’s disease, experts are pushing for…
There are plenty of gifts designed specifically for people living with dementia that can be helpful, calming or stress-relieving, whether they’re intended to spur…
This article is part of the Journey to Diagnosis series, produced by Being Patient with support provided by Eli Lilly. Creativity can flourish for…
This article is part of the Diversity & Dementia series, produced by Being Patient with support provided by Eisai. When a loved one has…
This article is part of the Diversity & Dementia series, produced by Being Patient with support provided by Eisai. Black Americans have nearly double…
This past three months in the Alzheimer’s drug development space have seen a new FDA approval for a symptomatic treatment, a couple failed phase…
At the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain, scientists and drug development companies gathered to report on recent successes…